White Pine Capital LLC acquired a new position in Merck & Co., Inc. (NYSE:MRK – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 34,086 shares of the company’s stock, valued at approximately $4,953,000. Merck & Co., Inc. accounts for approximately 1.2% of White Pine Capital LLC’s investment portfolio, making the stock its 15th biggest position.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. Round Rock Advisors LLC boosted its position in shares of Merck & Co., Inc. by 0.7% during the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after buying an additional 66 shares during the period. Cypress Wealth Services LLC grew its stake in shares of Merck & Co., Inc. by 0.5% during the third quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock valued at $1,960,000 after buying an additional 69 shares during the last quarter. Code Waechter LLC raised its holdings in shares of Merck & Co., Inc. by 3.4% in the third quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock worth $317,000 after buying an additional 71 shares during the period. Quest 10 Wealth Builders Inc. raised its holdings in shares of Merck & Co., Inc. by 12.2% in the third quarter. Quest 10 Wealth Builders Inc. now owns 699 shares of the company’s stock worth $102,000 after buying an additional 76 shares during the period. Finally, Cascade Financial Partners LLC raised its holdings in shares of Merck & Co., Inc. by 0.5% in the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after buying an additional 80 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.
Merck & Co., Inc. Price Performance
Shares of MRK stock opened at $147.74 on Monday. The company has a market capitalization of $364.21 billion, a P/E ratio of 152.31, a P/E/G ratio of 6.77 and a beta of 0.13. The company’s 50-day simple moving average is $146.16 and its two-hundred day simple moving average is $128.61. Merck & Co., Inc. has a one year low of $91.49 and a one year high of $156.92. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The firm had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter in the previous year, the firm posted $2.58 earnings per share. The company’s revenue was up 4.7% on a year-over-year basis. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.82 EPS for the current year.
More Merck & Co., Inc. News
These are some of the MRK news items that stood out recently:
- Positive Sentiment: The EMA’s CHMP recommended expanding ENFLONSIA’s use to help prevent severe RSV lower respiratory tract disease in vulnerable children up to 24 months old, including through their second RSV season. The broader eligible population could support the medicine’s commercial opportunity in Europe. Merck ENFLONSIA CHMP recommendation
- Positive Sentiment: The CHMP also recommended WELIREG plus lenvatinib for adults with advanced clear-cell renal cell carcinoma after anti-PD-1/PD-L1 treatment. This would extend WELIREG into another treatment setting and expand Merck’s oncology portfolio in Europe. Merck WELIREG CHMP recommendation
- Neutral Sentiment: Both decisions are CHMP recommendations; European Commission approval is still needed. Any financial contribution will also depend on launch timing, uptake and competition.
Analysts Set New Price Targets
MRK has been the subject of a number of research analyst reports. Sanford C. Bernstein raised their price target on Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a research note on Tuesday, August 4th. BMO Capital Markets upped their price objective on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, August 20th. Barclays increased their target price on Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an “overweight” rating in a research note on Monday, October 26th. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price for the company in a research report on Wednesday, August 12th. Finally, Morgan Stanley decreased their target price on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $155.74.
Check Out Our Latest Stock Analysis on Merck & Co., Inc.
About Merck & Co., Inc.
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Further Reading
- Five stocks we like better than Merck & Co., Inc.
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
